BiPar initiates testing of anticancer compound
BSI-201 is the first of a new class of cancer therapies that selectively induces tumor cell death by inhibiting enzyme function central to tumor survival. The drug is
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.